Skip to main content
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Belgium and Netherlands initiated a unique international pilot project Belgium-Netherlands Funding of International Trials (BeNeFIT) to carry out non-commercial practice-oriented comparative clinical studies

15 Dec 2017

In the end of November, the Belgian Health Care Knowledge Centre (KCE) and the Netherlands Organisation for Health Research and Care innovation (ZonMw) signed an agreement to invest 6 million euros for Belgium-Netherlands Funding of International Trials (BeNeFIT). This Belgium-Netherlands collaboration is aimed to carry out non-commercial practice-oriented comparative studies that should be performed by Belgian and Dutch institutions. Only non-commercial organisations can submit a proposal. Additionally, Belgian and Dutch institutions will be invited to submit proposals for research work in January, 2018. The approved research will be carry out by at least two Belgian and two Dutch institutions.

Following studies are considered eligible for funding:

  • Research of different types of technologies (medicines, medical devices, diagnostic tests and surgery) that are currently in use and eligible for reimbursement
  • Research of two treatment options for comparison  (including active treatment, placebo or no treatment)

Following studies are not considered for funding:

  • Implementation research
  • Studies on the organisation of Health Care (Health services Research)
  • Ongoing studies and studies that are currently recruiting of participants
  • Studies on new interventions and innovation

See full information in English here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.